Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2AQW7
|
|||
| Drug Name |
ABBV-154
|
|||
| Drug Type |
Antibody drug conjugate
|
|||
| Indication | Crohn disease [ICD-11: DD70; ICD-10: K50, K50.9; ICD-9: 555] | Phase 2 | [1] | |
| Rheumatoid arthritis [ICD-11: FA20; ICD-9: 729] | Phase 2 | [2] | ||
| Company |
AbbVie
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05068284) A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Crohn's Disease (CD): AIM-CD. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04888585) A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs). U.S.National Institutes of Health. | |||
| REF 3 | Discovery of ABBV-154, an anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody-Drug Conjugate (iADC). J Med Chem. 2023 Sep 14;66(17):12544-12558. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.